Company intelligence / Profile preview

Artis Biotech

Beijing, Beijing, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Artis Biotech is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary lipid nanoparticle (LNP) delivery platform to design highly stable and efficient nucleic acid drugs. Its lead program is an mRNA vaccine targeting COVID-19, which has progressed into Phase 2 clinical trials. Beyond infectious diseases, Artis Biotech is expanding its pipeline into oncology and protein replacement therapies. The company aims to address unmet medical needs through its integrated mRNA design and manufacturing capabilities.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyVaccine
Industry: Biotech

Beyond the preview

Go deeper on Artis Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artis Biotech.

Explore the full profile